# Forty Seven

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/forty-seven

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.fortyseveninc.com
- Total disclosed funding: $150M
- Latest round: Series B (Oct 17, 2017)
- Investors on record: 5

## About

Forty Seven, Inc. is a biopharmaceutical company focused on advancing novel immunotherapies for treating cancer. Their innovative approaches aim to engage the immune system to eliminate tumors and improve patient outcomes.Founded in 2015, Forty Seven, Inc. is based in Menlo Park, US. The company specializes in developing immunotherapies aimed at cancer treatment. In June 2018, it successfully raised USD 113 mn in an IPO, selling 7 million shares at USD 16 per share. The company has completed five deals to date, with its latest round being a Trade Sale in which it raised a total of USD 4,900 mn, primarily backed by Gilead Sciences, Inc.Forty Seven, Inc. focuses on developing innovative immunotherapy treatments for cancer patients. Their product lineup includes therapies that harness the power of the immune system to target and destroy cancer cells, providing critical treatment options for patients suffering from various forms of cancer.In the most recent year available, Forty Seven, Inc. recorded revenue of USD 15.68 mn with an EBITDA of USD -86.95 mn, reflecting its ongoing investment in research and development as it expands its therapeutic offerings.Forty Seven, Inc. aims to enhance its product portfolio by launching new immunotherapy treatments designed for specific cancer types, with detailed timelines yet to be announced. The company is also targeting expansion into international markets in Europe and Asia by 2025. Recent funding from the IPO will be utilized to accelerate product development and broaden its clinical trials, ensuring effective treatment options are accessible to a wider patient base.

## Funding rounds

- Series B, Oct 17, 2017, $75M — Lightspeed Venture Partners, Sutter Hill Ventures, Clarus Ventures, Wellington Management, GV
- Series A, Feb 24, 2016, $75M — Lightspeed Venture Partners, Sutter Hill Ventures, Clarus Ventures, GV

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A, Series B
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series A, Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B